Background: Pancreatic cancer is one of the cancers where anti-PD-L1/PD-1 immunotherapy has been unsuccessful. What confers pancreatic cancer resistance to checkpoint immunotherapy is unknown. The aim of this study is to elucidate the underlying mechanism of PD-L1 expression regulation in the context of pancreatic cancer immune evasion. Methods: Pancreatic cancer mouse models and human specimens were used to determine PD-L1 and PD-1 expression and cancer immune evasion. Histone methyltransferase inhibitors, RNAi, and overexpression were used to elucidate the underlying molecular mechanism of PD-L1 expression regulation. All statistical tests were two-sided. Results: PD-L1 is expressed in 60% to 90% of tumor cells in human pancreatic carcinomas and in nine of 10 human pancreatic cancer cell lines. PD-1 is expressed in 51.2% to 52.1% of pancreatic tumor-infiltrating cytotoxic T lymphocytes (CTLs). Tumors grow statistically significantly faster in FasL-deficient mice than in wild-type mice (P ¼ .03-.001) and when CTLs are neutralized (P ¼ .03-<.001). H3K4 trimethylation (H3K4me3) is enriched in the cd274 promoter in pancreatic tumor cells. MLL1 directly binds to the cd274 promoter to catalyze H3K4me3 to activate PD-L1 transcription in tumor cells. Inhibition or silencing of MLL1 decreases the H3K4me3 level in the cd274 promoter and PD-L1 expression in tumor cells. Accordingly, inhibition of MLL1 in combination with anti-PD-L1 or anti-PD-1 antibody immunotherapy effectively suppresses pancreatic tumor growth in a FasL-and CTL-dependent manner. Conclusions: The Fas-FasL/CTLs and the MLL1-H3K4me3-PD-L1 axis play contrasting roles in pancreatic cancer immune surveillance and evasion. Targeting the MLL1-H3K4me3 axis is an effective approach to enhance the efficacy of checkpoint immunotherapy against pancreatic cancer.
PD-1 is a T cell inhibitory receptor that interacts with its ligand PD-L1 to maintain self-tolerance and to protect against excessive tissue damage induced by immune responses, and thus functions as an immune checkpoint under physiological conditions (1) . Under pathological conditions such as cancer, PD-L1 is often upregulated in tumor cells, resulting in potent immune suppression and tumor immune escape (2) (3) (4) (5) (6) (7) (8) . Accordingly, blocking the interactions between PD-1 and PD-L1 can induce durable efficacy of tumor suppression in both mouse tumor models and human cancer patients (9) (10) (11) (12) (13) . However, human pancreatic cancer stands out as one cancer that does not respond to checkpoint immunotherapy (14) . The mechanism underlying pancreatic cancer resistance to anti-PD-1/PD-L1 immunotherapy is unknown, but it has been suggested that the expression level of PD-L1 in tumor cells is a key determinant of checkpoint immunotherapy efficacy (9, 15, 16) PD-L1 is constitutively expressed and induced by inflammatory cytokines in the tumor microenvironment in human cancers (15, 17, 18) . It has been reported that oncogenes such as AKT and STAT3 directly regulate constitutive PD-L1 expression in tumor cells (19, 20) . IFNc is a proinflammatory cytokine secreted by activated T and natural killer (NK) cells and acts as an essential component of the host cancer immune surveillance system (21, 22) . However, IFNc also acts as a master inducer of PD-L1 in tumor cells (16) (17) (18) 23) , suggesting that tumor cells may sense the elevated IFNc as a "threat" in the tumor microenvironment and adapt it by upregulating PD-L1. These studies firmly established the role of oncogenes and inflammatory cytokines as key regulators of PD-L1 expression in tumor cells. We aimed at testing the hypothesis that PD-L1 expression is regulated by an epigenetic mechanism in pancreatic cancer and epigenetic targeting of PD-L1 is an effective approach to enhance the efficacy of checkpoint immunotherapy for pancreatic cancer.
Methods

Cancer Cells
Pancreatic, colon, and melanoma cancer cell lines were obtained from American Type Culture Collection (ATCC; Manassas, VA). ATCC has characterized these cells by morphology, immunology, DNA fingerprint, and cytogenetics. PANC02-H7 cells were kindly provided by Dr. Min Li (University of Oklahoma Health Sciences Center) and characterized as previously described (24, 25) . UN-KC-6141 cells were kindly provided by Dr. Surinder Batra (University of Nebraska Medical Center) and characterized as previously described (26) . Human pancreatic cancer specimens were obtained from the Georgia Cancer Center tumor bank and from the Cooperative Human Tissue Network (CHTN) Southern Division. The tumor tissue specimens were analyzed by a board-certified pathologist.
Orthotopic Mouse Pancreatic Cancer Models
Six-to eight-week-old female WT C57BL/6 and fasl gld mice were obtained from the Jackson Laboratory (Bar Harbor, ME). Mice were continuously anesthetized with isoflurane (1%-3% in oxygen). A small abdominal incision at the right side near the spleen was made, and the pancreas was identified with sterile gauze. Tumor cells (1x10 4 cells in 20 lL saline) were injected into the pancreas using a sterile tuberculin syringe. The abdomen was closed with wound clips. All mouse studies were performed according to protocols approved by Augusta University Institutional Animal Care and Use Committee.
Statistical Analysis
All statistical analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC), and statistical significance was assessed using an alpha level of .05. Two-factor ANOVA was used to examine the interaction of treatments on tumor weight and volume within tumor cell type. A Tukey-Kramer multiple comparison procedure on the means of the interaction term was used to examine pair-wise post hoc differences between groups to control the overall statistical significance level. Two-sample t tests were used to determine differences in tumor weight and tumor volume between control and treatment groups or between WT C57BL/6 and fasl gld mice. All statistical tests were two-sided. Methods and Supplementary Tables 1 and 2 (available online) .
Additional methods are included in the Supplementary
Results
PD-L1 and PD-1 Expression Profiles in Pancreatic Tumor Cells and Pancreatic Tumor-Infiltrating Cytotoxic T Lymphocytes
To determine the expression profiles of PD-L1 and PD-1 in tumor-bearing mice, two orthotopic pancreatic carcinoma mouse models were established ( Figure 1, A and E) . Both PANC02-H7 and UN-KC-6141 cells express PD-L1 in vitro, and the orthotopic tumor cells express statistically significantly higher levels of PD-L1 in in vivo than in in vitro cultured tumor cells (P < .001) (Figure 1, B and F ). An average of 51.2% and 52.1% of tumor-infiltrating CD8 
MLL1-Mediated H3K4 Trimethylation in the CD274 Promoter Region and PD-L1 Expression
In a screening for epigenetic mechanisms that regulate PD-L1 expression in pancreatic cancer cells, we observed enrichment of H3K4me3 marks in the proximal cd274 promoter region in both human ( Figure 2 , A and B) and mouse ( Figure 2 , A and C) pancreatic cancer cells cultured in vitro. Chromatin immunoprecipitation (ChIP) analysis revealed that H3K4me3 levels are enriched in the proximal cd274 promoter region in both PANC02-H7 and UN-KC-6141 orthotopic tumors, whereas a minimal level of H3K4me3 was detected in the cd274 promoter region in normal pancreas in vivo ( Figure 2D ). The tumor cells exhibit the highest H4K4me3 level in a region upstream of the transcription initiation region (Figure 2 , A-D). ChIP sequencing of chromatin fragments from normal pancreas and orthotopic PANC02-H7 and UN-KC-6141 tumor tissues revealed a cluster of H3K4me3 marks around the cd274 transcription start site, and H3K4me3 marks are enriched in the cd274 promoter region around -1000 to þ 2000 in the tumor tissues ( Figure 2E ). Analysis of histone methyltransferases (HMTase) revealed that MLL1, one of the H3K4 methylation-specific HMTases (27, 28) , is elevated in the orthotopic pancreatic tumor tissues both on the mRNA and the protein level ( Figure 2F ). PD-L1 is expressed in the normal pancreas tissues, albeit at a lower level ( Figure 2F ). PD-L1 transcript level is more elevated in the tumor cells than in the normal pancreatic tissues ( Figure 2F ). ChIP analysis revealed that MLL1 is directly associated with the cd274 promoter region in mouse pancreatic cancer cells in vitro and the orthotopic pancreatic tumor tissues in vivo ( Figure 2G ). Silencing MLL1 expression dramatically decreased H3K4me3 level in the CD274 promoter region (P ¼ .03) and PD-L1 mRNA level (P ¼ .001) in human pancreatic cancer cells ( Figure 2H ). Similarly, silencing MLL1 expression notably reduced the H3K4me3 level in the cd274 promoter region (P ¼ .02) and statistically significantly downregulated the PD-L1 mRNA level (P ¼ .002) in mouse pancreatic cancer cells ( Figure 2I ). Figure 1A , available online). As a specificity control, an optimized mouse MLL1 fulllength cDNA was made and cloned into a mammalian expression vector. This optimized MLL1-expressing plasmid was cotransfected with MLL1 siRNA to the tumor cells. Analysis of the optimized MLL1 mRNA using optimized MLL1 sequencespecific PCR primers indicates that it is resistant to WT MLL1-specific siRNA and that overexpression of this optimized MLL1 plasmid rescued WT MLL1 siRNA-mediated downregulation of PD-L1 as measured by PD-L1 mRNA level and protein level (Supplementary Figure 1 , B and C, available online).
MLL1 and PD-L1 Expression Patterns in Human Pancreatic Cancer Tissues
Human pancreatic carcinoma specimens from 13 human pancreatic cancer patients were then analyzed by immunohistochemistry (IHC) using a human MLL1-specific antibody and a human PD-L1-specific antibody (29) . Human tonsil and adrenal tumor tissues were used as positive controls. 
MLL1 and PD-L1 Expression in Pancreatic Cancer Cells
We then made use of a recently identified HMTase inhibitor verticillin A that inhibits MLL1 (30) . Verticillin A inhibits MLL1 activity with an IC 50 of 0.8 lM (Supplementary Figure 4A , available online). However, verticillin A does not inhibit global H3K4 methylation in human and mouse pancreatic cancer cells (Supplementary Figure 4B , available online). Interestingly, verticillin A statistically significantly decreased the H3K4me3 level in the cd274 promoter region in a dose-dependent manner in pancreatic tumor cells in vitro (P ¼ .02) ( Figure 4A ). Consistent with the decreased H3K4me3 levels in the cd274 promoter region, verticillin A dramatically decreased the PD-L1 mRNA level (P ¼ .01) ( Figure 4B ) and the protein level (P ¼ .007) ( Figure 4C ) in the tumor cells in vitro. Treatment of tumor-bearing mice with verticillin A also decreased the H3K4me3 level in the cd274 promoter region in the orthotopic tumor tissues (P ¼ .04) ( Figure 4D ). PD-L1 mRNA level (P ¼ .02) ( Figure 4E ) and protein level (P < .001) ( Figure 4F ) were also statistically significantly decreased in the orthotopic tumor tissues in vivo.
Chaetocin is a potent HMTase inhibitor (31) . Interestingly, chaetocin also exhibits potent inhibitory activity for MLL1 ( Figure 5A ). Treatment of human pancreatic cancer cells with chaetocin statistically significantly decreased the H3K4me3 level in the CD274 promoter region (P ¼ .002) ( Figure 5B ). Consistent with decreased H3K4me3 level, PD-L1 protein level is statistically remarkably decreased in chaetocin-treated human pancreatic cancer cells (P < .001) ( Figure 5C ). Although chaetocin inhibits SUV39H1 and SUV39H2, HMTases that mediate H3K9me3 (31), the H3K9me3 level is low in the CD274 promoter region in human pancreatic cancer cells ( Figure 5D ). Conversely, overexpression of MLL1 increased MLL1 mRNA level, resulting in increased PD-L1 mRNA and protein levels in both PANC02-H7 and UN-KC-6141 cells (P < .01) (Supplementary Figure 5 , available online).
Role of FasL in Suppression of Pancreatic Tumor Growth In Vivo
The Fas-mediated apoptosis pathway plays a key role in host cancer immune surveillance against spontaneous B lymphoma and colon carcinoma (22, 32) . In addition to H3K4me3, verticillin A also targets H3K9me3 to increase Fas expression in human colon cancer cells (30) 
Discussion
H3K4 methylation in mammalian cells is catalyzed by multiple HMTases (33) . Homozygous MLL SET-domain knockout mice have a relatively normal phenotype (34) , and the histone methyltransferase activity of MLL1 seems dispensable for hematopoiesis (35) . Furthermore, the effects of MLL1 deficiency on H3K4me3 and gene expression are minimal in mouse embryonic stem cells (36) . However, MLL1 is essential for H3K4me3-dpendent Hox gene transcription activation in leukemia (27, 28, 37, 38) . Here we show that MLL1 is highly expressed in pancreatic cancer cells. We also show an H3K4me3 cluster present in the cd274 promoter region flanking the transcription start site in a normal mouse pancreas. However, H3K4me3 level is dramatically upregulated in the cd274 promoter region in pancreatic tumor tissues in vivo. We further show that inhibition of MLL1 activity or silencing of MLL1 expression decreases H3K4me3 level in the CD274 promoter region and downregulates PD-L1 expression in pancreatic tumor cells. Conversely, overexpression of MLL1 increased PD-L1 expression in pancreatic tumor cells. Our data thus extend MLL1 function to H3K4 methylation and PD-L1 transcription activation in pancreatic cancer cells. Immune suppression is a major limiting factor for cancer immunotherapy (39) (40) (41) . Immune checkpoint blockade reverses immune suppression to activate tumor-reactive CTLs that directly target tumor cells for apoptosis (11, 16, 42) . CTLs primarily use the perforin-and Fas-mediated effector mechanisms to induce tumor cell apoptosis. Recent studies have shown that immune suppressive cells selectively inhibit the perforin pathway of tumor-specific CTLs without downregulating CTL activation in vivo (43, 44) , suggesting that the Fas-mediated effector mechanism may be functional in the immune-suppressive tumor microenvironment. Indeed, it has been shown that the Fas-FasL axis represses spontaneous melanoma metastasis (45) , and FasL-mediated immune surveillance by T cells is essential for the control of spontaneous B cell lymphomas (32) . Here we demonstrated that pancreatic tumor-infiltrating CTLs are FasL þ and FasL plays a key role in the suppression of pancreatic cancer growth in vivo. Our data therefore reveal a key role of FasL of host CTLs in cancer immune surveillance against pancreatic cancer growth in vivo.
One limitation of this study is that in addition to MLL1, verticillin A also inhibits five other HMTases (Supplementary Figure  4A, available online) . Therefore, the specificity and toxicity of verticillin A as an epigenetic agent in cancer therapy remains to be further studied. Nevertheless, this proof of concept study indicates that epigenetic targeting of H3K4me3 is potentially effective in enhancing the efficacy of pancreatic cancer checkpoint immunotherapy.
Pancreatic ductal adenocarcinoma is a highly aggressive cancer where prognosis has not been improved over the past few decades (46) . Pancreatic cancer is also one of the few cancers that does not respond to checkpoint immunotherapy (14) . It has been shown that the expression level of PD-L1 is positively correlated with the efficacy of anti-PD-1/PD-L1 immunotherapy (9). In the literature, it has been reported that PD-L1 ARTICLE expression is sparse in human pancreatic carcinoma tissues (42, 47) . However, we show here that human pancreatic carcinoma expresses abundant PD-L1 and the majority of tumor cells are PD-L1-positive. Furthermore, nine of the 10 human pancreatic cancer cell lines are PD-L1-positive and no PD-L1 -tumor cells are observed in these nine tumor cell lines. In this study, a specific and sensitive anti-PD-L1 MAb (clone 28-8) (29) was used, and this MAb has recently been approved by US Food and Drug Administration for detecting PD-L1 protein in human cancer patient tumor specimens. The discrepancy between our study and the reports in the literature might be due to the specificity and sensitivity of antibodies used, which requires further study. Nevertheless, the abundant PD-L1 protein level in human pancreatic cancer cells also suggests that the expression level of PD-L1 might be a determining factor of the PD-1/PD-L1 pathway-mediated cancer immune resistance against elimination by endogenous tumor-specific T cells in pancreatic cancer. This notion is supported by our observation that repression of MLL1-mediated PD-L1 expression with verticillin A statistically significantly increases the efficacy of anti-PD-L1/PD-1 immunotherapy against the established pancreatic cancer. Therefore, elevated PD-L1 expression levels in vivo might be a limiting factor for the poor response of pancreatic cancer to anti-PD-L1/ PD-1 immunotherapy. However, although verticillin A and anti-PD-L1 alone exhibited statistically remarkable tumor suppressive activity, no synergistic effects were observed between 
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these two agents, which is probably because of the fact that these two agents, when combined, almost eradicated the tumors. Further studies for various agent doses and treatment time are required. Nevertheless, our findings support the notion of combined epigenetic agents and immunotherapy to combat cancer (48) . Specifically, the use of an epigenetic agent, such as an MLL1 inhibitor, to target H3K4me3 to decrease PD-L1 expression is potentially an effective approach to augment the efficacy of checkpoint blockade immunotherapy against deadly pancreatic cancer. Tumor volume and tumor weight were analyzed by two-side t tests and are presented in the right panels. E and F) Tumor tissues from both PANC02-H7 (E) and UN-KC-6141 (F) tumor-bearing mice as shown in Figure 7 , A and B, were collected after the indicated treatments and analyzed for CD8 and IFNc mRNA levels by quantitative polymerase chain reaction. The differences between control and treatment group were analyzed by two-sided t tests. Column: mean; bar: SD. WT ¼ wild-type.
